Delivery Order SPE2DB22D9311-SPE2DB25FP6ZM
- Not listed
- This delivery order for $2,362.08 was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of ENGERIX-B 20 MCG/ML SYRN, a hepatitis B vaccine, to the Defense Logistics Agency (DLA) Medical Supply Chain. The order, placed under the DLA's SPE2DB program, has a firm fixed price and an ultimate completion date of July 12, 2024. DMS Pharmaceutical Group specializes in providing a wide range...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $1,181.70 by the Defense Logistics Agency's Medical Supply Chain on August 11, 2025. The contract calls for the delivery of ENGERIX-B 20 MCG/ML syringes, a hepatitis B vaccine, with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation, allowing DMS Pharmaceutical Group...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $2,603.16 firm fixed-price delivery order is for the supply of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine, with no set-aside designation. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
- This federal contract award, valued at $4,724.16, was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order to supply the Defense Department with ENGERIX-B 20 MCG/ML SYRN, a hepatitis B vaccine. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency (DLA) on July 18, 2025, for ENGERIX-B pediatric hepatitis B vaccine (10 micrograms/0.5 milliliter syringes). This firm fixed-price delivery order carries a ceiling value of $4,243.68 and is scheduled for completion by July 21, 2025. The contract utilizes no set-aside designation, and performance will occur at the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,878.00 by the Defense Logistics Agency's Medical Supply Chain on August 5, 2025, for the supply of ENGERIX-B 20 MCG/ML syringes. This firm fixed-price delivery order, which carries an ultimate completion date of August 8, 2025, represents a discrete procurement action under the company's existing Indefinite Delivery Contract with DLA....
- This federal contract award, valued at $5,905.20, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award is a firm fixed-price delivery order for the supply of ENGERIX-B 20 MCG/ML SYRN, a pharmaceutical product, with an ultimate completion date of October 29, 2024. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 with...
- This federal contract award, valued at $5,905.20, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order for the supply of ENGERIX-B 20 MCG/ML SYRN, a pharmaceutical product. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,756.00 contract is for the delivery of ENGERIX-B 20 MCG/ML SYRNML, a hepatitis B vaccine, with a period of performance through May 28, 2025. DMS Pharmaceutical Group Inc. has a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,969.50 firm fixed-price delivery order is for the supply of ENGERIX-B 20 MCG/ML SYRN, a hepatitis B vaccine. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at $499,999,999 and valid through November 2026. The IDC...
- SPE2DB22D9311Indefinite Delivery Contract
- SPE2DB22D9311-SPE2DB25FP6ZMDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,607.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of ENGERIX-B PEDI 10 MCG/0.5 SYRN 0.5ML, a pediatric hepatitis B vaccine. The award, issued on July 18, 2025, with an ultimate completion date of July 21, 2025, carries a firm fixed-price contract type with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with DLA under the SPE2DB program, a $499.9 billion vehicle that enables the agency to procure a comprehensive range of pharmaceutical products and medical supplies to support military health facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain through consistent contract performance and a robust portfolio of pharmaceutical deliveries to the DLA. The company's core business involves distributing branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to Department of Defense healthcare facilities. By leveraging its woman-owned small business status and capabilities as a pharmaceutical wholesaler, DMS Pharmaceutical Group has successfully competed in federal procurement markets without requiring specific set-aside protections, maintaining a strong position as a preferred vendor for medical supply distribution across the military healthcare system.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 7/18/25 |